Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales

Nov 16 2022

• By Malcolm Spicer

• Source: Shutterstock

Related Content

US FDA Elevates Controlled Substances Coordinator To New Deputy CDER Director Role

Jul 18 2022

US FDA Expects No Change In Naloxone Access Barrier If Prices High For Potential OTC Products

Aug 30 2022

OTC Naloxone May Get Another Push From US FDA As Agency Prepares Novel Switch Proposed Rule

May 03 2022

Naloxone Switch NDA Submitted As US FDA Signals Nonprescription Access Looks Safe, Effective

Nov 16 2022

FDA Has Model Drug Facts Labels For OTC Naloxone, Wants Switch Proposals

Jan 18 2019

Related Companies

Emergent BioSolutions, Inc.

Hikma Pharmaceuticals plc

Additional Topics

International United States Drug Approval Standards FDA Prescription To OTC Switch Commercial Consumer Compliance Distribution Ingredients Manufacturing OTC Drugs Policy Politics Regulation Safety BioPharmaceutical

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window